1.
2.
Pediatr Blood Cancer
; 67(12): e28516, 2020 12.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32573959
Assuntos
Antineoplásicos Alquilantes/efeitos adversos , Neoplasias Encefálicas/tratamento farmacológico , Diabetes Insípido Neurogênico/patologia , Neoplasias Neuroepiteliomatosas/tratamento farmacológico , Doenças Raras/patologia , Temozolomida/efeitos adversos , Neoplasias Encefálicas/patologia , Criança , Diabetes Insípido Neurogênico/induzido quimicamente , Humanos , Masculino , Neoplasias Neuroepiteliomatosas/patologia , Prognóstico , Doenças Raras/induzido quimicamente
3.
Oncotarget
; 10(4): 551-557, 2019 Jan 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30728904
RESUMO
Outcomes for children with high-grade gliomas (HGG) remain dismal despite aggressive treatment strategies. The use of targeted therapy for BRAFV600E mutated malignancies including HGG is being explored as a potentially well tolerated and effective therapeutic option. The results of adult melanoma studies demonstrating that combination therapy with BRAF inhibitors and MEK inhibitors results in prolonged survival led us to employ this treatment strategy in children with BRAFV600E mutated HGG. In this case series, we describe three pediatric patients with HGG with confirmed BRAFV600E mutation who demonstrated responses to combination therapy with dabrafenib and trametinib.